Titan Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>TP</div>
TTNP -- USA Stock  

USD 0.18  0.01  5.26%

It appears that Titan Pharmaceuticals may not have a good chance to recover from the recent decline as its shares fell again. This firm's current daily volatility is 8.93 percent, with a beta of 0.2 and an alpha of -1.03 over DOW. As many millenniums are trying to avoid the recent volatility, we are going to recap Titan Pharmaceuticals a little further to understand its historical price patterns. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a week ago
View all stories for Titan Pharmaceuticals | View All Stories
Should you acquire Titan after the recent volatility decline?
Titan Pharmaceuticals currently holds about 5.5 M in cash with (16.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. The entity has a beta of 0.1956, which indicates not very significant fluctuations relative to the market. Let's try to break down what Titan's beta means in this case. As returns on the market increase, Titan Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Titan Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Titan Pharmaceuticals current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Titan Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Titan Pharmaceuticals has an expected return of -0.91%. Please be advised to validate Titan Pharmaceuticals jensen alpha and semi variance to decide if Titan Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
Investing in Titan Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Titan Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

Watch out for price decline

Please consider monitoring Titan Pharmaceuticals on a daily bases if you are holding a position in it. Titan Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Titan Pharmaceuticals stock to be traded above the $1 level to remain listed. If Titan Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Titan Pharmaceuticals's Liquidity

Titan Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Titan Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Titan Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Titan Pharmaceuticals's total debt and its cash.

How Titan utilizes its cash?

To perform a cash flow analysis of Titan Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Titan Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Titan Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Titan Pharmaceuticals Net Cash Flow from Operations is very stable at the moment as compared to the past year. Titan Pharmaceuticals reported last year Net Cash Flow from Operations of 5.66 Million

Titan Pharmaceuticals Correlation with Peers

Investors in Titan can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Titan Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Titan Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Titan is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Titan for more details

Breaking it down a bit more

Titan Pharmaceuticals owns Efficiency Ratio (i.e. Sharpe Ratio) of -0.1, which indicates the firm had -0.1% of return per unit of risk over the last month. Macroaxis standpoint towards measuring the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Titan Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate Titan Pharmaceuticals coefficient of variation of (887.72), and Risk Adjusted Performance of (0.13) to confirm the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will Titan Pharmaceuticals continue to go nuts?

Recent total risk alpha indicator falls down to -1.6. Possible price boost? Titan Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Titan Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Titan Pharmaceuticals volatility. Titan Pharmaceuticals is a potential penny stock. Although Titan Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Titan Pharmaceuticals. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Takeaway

Although some companies in the biotechnology industry are either recovering or due for a correction, Titan Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 14th of November 2020, we believe Titan Pharmaceuticals is currently undervalued. It barely shadows the market and projects significantly high odds of distress in the next two years. However, our present 30 days 'Buy-Sell' recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Titan Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com